Conjugating mAb targeting CD30 and cytotoxic MMAE empowers brentuximab vedotin with the ability to enter into the CD30-positive lymphoma cells and interfere with microtubule formation, thus causing cell cycle arrest and inducing apoptosis [14,15]. The gene discussed is TNFRSF8; the disease is lymphoma.